时间的河流之上，2025年的深圳正驶向特区建立45周年的历史航标。四十五载光阴，这座因改革而生的 城市，创造了一个关于"时间"与"效率"的奇迹。当外界试图解读"深圳密码"时，常常会将目光投向深圳 的经济大区、工业大区宝安区，这里的创业故事像是与时间签下的"军令状"，它们发展路径不同，但共 同以"深圳精神"书写了一部多元且充满韧性的"宝安故事"。 今朝时代股份有限公司(以下简称"今朝时代")，16年深耕超级电容，从被外资垄断的夹缝中突围，成为 实现细分领域全球第一的"扫地僧"；影石创新科技股份有限公司(以下简称"影石创新")，从360°无死角 的沉浸式全景相机起步，用70g的重量重新定义行业标准，加冕"新消费冠军"，最终敲响科创板的铜 锣。它们用执着与创新，共同勾勒出了"宝安军团"的剪影，它们的故事，是关于时间的坚守与创新的突 围，更是对"为何是宝安"的最佳注解。 创业原点: 技术极客与制造匠人"梦"的开始 宝安的创业光谱上，今朝时代向内扎根，解决的是"有没有"的焦虑；影石创新向外破圈，探索的是"好 不好"的想象。两条不同的创业路径，指向同一个目标:打破现状，定义未来。 "创业就像行军打仗，该先有一个'番号'。 ...

Financial Data and Key Metrics Changes - The company reported Q1 2025 revenue of $132 million, at the high end of the guided range, with EPS of $0.18, also at the midpoint of guidance [11][18] - Gross margins for Q1 were 48.7%, down 450 basis points year-over-year, primarily due to a supply agreement impacting margins and unfavorable customer mix [18] - Cash from operations exceeded the high end of the guided range, driven by higher than expected customer prepayments [20][21] Business Line Data and Key Metrics Changes - MedTech and Specialty Audio revenue was $60 million, slightly up year-over-year but seasonally down from Q4 [11][18] - Precision Device segment revenues were $73 million, flat compared to Q4, with gross margins at 35.7%, flat year-over-year [12][18] - The company expects year-over-year revenue growth to accelerate in Q2 2025, driven by strong demand in MedTech and Specialty Audio [12][16] Market Data and Key Metrics Changes - The company estimates that less than 5% of revenue is subject to current tariffs, with less than 3% of cost of goods sold impacted [6][8] - Inventory levels at distributors are normalizing, leading to increased order activity, particularly in the industrial market [33][52] Company Strategy and Development Direction - The company is focused on growth in 2025, with expectations for year-over-year revenue growth and strong cash generation [15][24] - The management highlighted the importance of partnerships with customers to drive innovation and performance enhancements in products [12][16] - The company plans to explore acquisition opportunities and maintain manageable debt levels while investing in capacity expansion [14][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow despite the current tariff environment, citing essential nature of products in MedTech and defense sectors [4][10] - The company is monitoring the macroeconomic environment closely, particularly in the industrial market, but currently sees no significant impact on demand [10][33] - Management anticipates a stronger second half of 2025, driven by increasing order activity and a growing backlog [39][40] Other Important Information - The company repurchased $5 million in shares and reduced debt by $15 million during Q1 [14][21] - The company expects capital spending to be 5% of revenues as it increases investments in capacity expansion related to the specialty film line [23] Q&A Session Summary Question: Can you discuss overall end market customer exposure and outlook? - Management noted no change in demand and higher expectations for Q2 compared to the previous quarter, emphasizing the essential nature of products in MedTech and defense [30][32] Question: Any updates on the $75 million capacitor order for the energy market? - Management confirmed a substantial prepayment received in Q1, indicating strong customer commitment and no expected impact on delivery starting in 2026 [35] Question: Can you provide insights on gross margin trajectory for Q2 and Q4? - Management expects significant sequential improvement in gross margins, driven by increased capacity utilization and better customer mix [38][39] Question: Are there opportunities for market share gain from competitors? - Management acknowledged receiving inquiries from customers considering switching suppliers due to tariff impacts, particularly in the industrial space [45][46] Question: Can you comment on bookings and receivables? - Management reported strong bookings trends and noted that receivables were up due to timing of customer payments, with no collection issues [49][55]

Financial Data and Key Metrics Changes - The company reported Q1 2025 revenue of $132 million, at the high end of the guided range, with EPS of $0.18, also at the midpoint of guidance [11][19] - Gross margins for the MedTech and Specialty Audio segment were 48.7%, down 450 basis points year-over-year, primarily due to a supply agreement impacting margins [19] - Precision Devices segment revenues were $73 million, flat compared to Q4, with gross margins at 35.7%, unchanged from the previous year [13][20] Business Line Data and Key Metrics Changes - MedTech and Specialty Audio revenue was $60 million, slightly up year-over-year but seasonally down from Q4 [11][19] - Precision Devices segment saw a flat revenue performance, with production challenges in the specialty film line being addressed [13][20] - The company expects year-over-year revenue growth to accelerate in Q2 2025, driven by strong demand in MedTech and Specialty Audio [12][17] Market Data and Key Metrics Changes - The company estimates that less than 5% of revenue is subject to current tariffs, with less than 3% of cost of goods sold impacted [7][8] - Inventory levels at distributors have normalized to 3-3.5 months, indicating increased order activity [34][52] - The company is seeing strong bookings trends across most end markets, particularly in Precision Devices [15][52] Company Strategy and Development Direction - The company is focused on growth in 2025, with strong design wins and increasing backlog across its product portfolio [17] - There is an emphasis on exploring acquisition opportunities while maintaining manageable debt levels [16][22] - The upcoming Investor Day will detail future growth plans and competitive advantages [17][60] Management's Comments on Operating Environment and Future Outlook - Management remains cautious about the tariff environment but believes the company is well-positioned for growth despite potential impacts [5][10] - The outlook for the MedTech and defense sectors remains strong, with essential devices expected to maintain demand [32][33] - Management anticipates a stronger second half of 2025, driven by improved capacity utilization and demand recovery [41][42] Other Important Information - The company repurchased $5 million in shares and reduced debt by $15 million in Q1 2025 [16][22] - Capital spending is projected to be $7 million in Q2, with full-year capital spending expected to be 5% of revenues [24] Q&A Session Summary Question: Overall end market customer exposure and outlook - Management indicated no change in demand and higher expectations for Q2, particularly in essential devices like pacemakers and hearing aids [31][32] Question: Updates on the $75 million capacitor order - A substantial prepayment was received, indicating strong customer commitment with no expected delivery impacts [37] Question: Gross margin trajectory for Q2 and Q4 - Management expects significant sequential improvement in gross margins, projecting an exit range of 45% to 47% by year-end [40][44] Question: Potential for gaining market share from competitors - Management noted increased inquiries from customers considering switching suppliers due to tariff impacts, particularly in the industrial space [46][47] Question: Commentary on bookings and receivables - Bookings were strong, with inventory levels at distributors decreasing, indicating rising demand [52][56]